
CLIENT: | Large manufacturer with significant global penetration looking to understand the threat that biosimilars pose to its biologic portfolio as well as opportunities for developing biosimilars for other products in emerging markets. |
BUSINESS QUESTION: | What is the current regulatory, access / reimbursement and competitive landscape for biosimilars within each of the BRICKMT markets, and which threats or opportunities should be considered within a 5 year outlook? |
OUR APPROACH: | ISA built upon existing market knowledge, triangulated and validated data sources, and synthesized information to critically assess risks and opportunities.
|
RESULT: | The client developed a biologic defense and biosimilar manufacturing plan over the next five years throughout these seven emerging markets based upon ISA’s analyses and recommendations. |